medigraphic.com
Instituto Nacional de Salud Pública

2023, Number 3

<< Back Next >>

salud publica mex 2023; 65 (3)

Poor glycemic control: a public health challenge prepandemic and pandemic

Mares-Gutiérrez Y, Gallardo-Hernández A, Lazcano-Ponce E, Martínez-Franco AI, García-Minjares M, Martínez-González A

Language: Spanish
References: 34
Page: 227-235
PDF size: 376.72 Kb.


ABSTRACT

Objective. To compare glycemic control in patients with type 2 diabetes mellitus who attended primary healthcare units in Mexico City, prepandemic and during the COVID-19 pandemic. Materials and methods. Records of 23 912 diabetes patients were analyzed; 78.7% were from the prepandemic group (2016 to 2020) and 21.3% from the pandemic group (March 2020 to July 2021). Central tendency and dispersion measures were calculated, Student’s t-test and multiple logistic regression model were performed. Results. Patients with diabetes were mainly women (66.6 and 62.6%) with an average age of 59 and 58 years, respectively. Glycosylated hemoglobin (HbA1) levels were 7.7 in the prepandemic group and (8.0) in the pandemic group. The variables associated with poor glycemic control included period, HbA1 level, overweight, obesity, history of parents with diabetes, number of medications and type of insulin. Conclusions. Most patients with diabetes continued to have poor glycemic control in both groups. Patients in the pandemic group had poor glycemic control compared to the prepandemic group. After medical intervention, patients improved their glycemic control in both groups.


REFERENCES

  1. World Health Organization. WHO, Diabetes, Fact sheets. Fact sheets,Diabetes. 2021 [citado mayo 7, 2021]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/diabetes

  2. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD,Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetesprevalence for 2017 and projections for 2045. Diabetes Res Clin Pract.2018;138:271-81. https://doi.org/10.1016/j.diabres.2018.02.023

  3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N,et al. Global and regional diabetes prevalence estimates for 2019 andprojections for 2030 and 2045: Results from the International DiabetesFederation Diabetes Atlas, 9 th ed. Diabetes Res Clin Pract. 2019;157:1-10. [citado mayo 7, 2021]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31518657/

  4. Ritchie H, Spooner F, Roser M. Causes of Death. England: Global ChangeData Lab, 2018 [citado septiembre 2, 2022]. Disponible en: https://ourworldindata.org/causes-of-death

  5. Our World in Data. Diabetes prevalence. England: Global Change DataLab, 2022 [citado sepiembre 2, 2022]. Disponible en: https://ourworldindata.org/search?q=diabetes+prevalence

  6. Ugliara-Barone MT, Villarroel D, de Luca PV, Harnik SB, Lima BL de S,Wieselberg RJP, et al. COVID-19 impact on people with diabetes in Southand Central America (SACA region). Diabetes Res Clin Pract. 202;166:1-6.https://doi.org/10.1016/j.diabres.2020.108301

  7. World Health Organization. WHO. Pulse Survey on Continuity ofEssential Health Services during the COVID-19. Pandemic. 2020 [citadoseptiembre 2, 2022]. Disponible en: https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2020.1

  8. Barrio-Cortes J, Suárez-Fernández C, Bandeira-de Oliveira M, Beca-Martínez MT, Lozano-Hernández C, Del Cura-González I. Health servicesutilization in primary care in patients with chronic conditions according torisk levels. Rev Esp Salud Publica. 2019;93:1-15 [citado septiembre 2, 2022].Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/31488808 PMID 3148808

  9. Maddaloni E, Coraggio L, Pieralice S, Carlone A, Pozzilli P, Buzzetti R.Effects of COVID-19 lockdown on glucose control: continuous glucosemonitoring data from people with diabetes on intensive insulin therapy.Diabetes Care. 2020;43(8):e86-7. https://doi.org/10.2337/dc20-0954

  10. Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E.Glycemic control in type 1 diabetes mellitus during COVID-19 quarantineand the role of in-home physical activity. Diabetes Technol Ther.2020;22(6):462-7. https://doi.org/10.1089/dia.2020.0169

  11. Khader MA, Jabeen T, Namoju R. A cross sectional study reveals severedisruption in glycemic control in people with diabetes during and afterlockdown in India. Diabetes Metab Syndr Clin Res Rev. 2020;14(6):1579-84. https://doi.org/10.1016/J.DSX.2020.08.011

  12. Verma A, Rajput R, Verma S, Balania VKB, Jangra B. Impact of lockdownin COVID 19 on glycemic control in patients with type 1 Diabetes Mellitus.Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1213-6. https://doi.org/10.1016/j.dsx.2020.07.016

  13. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud yNutrición 2021 sobre Covid-19. México: INSP, 2021 [citado septiembre2, 2022]. Disponible en: https://insp.mx/novedades-editoriales/encuestanacional-de-salud-y-nutricion-2021-sobre-covid-19-resultados-nacionales

  14. Instituto Mexicano del Seguro Social. GPC diagnóstico y tratamientofarmacológico de la diabetes mellitus tipo 2 en el primer nivel deatención. Evidencias y recomendaciones. México: CENETEC, 2018 [citadoseptiembre 2, 2022]. Disponible en: https://imss.gob.mx/sites/all/statics/guiasclinicas/718GER.pdf

  15. Raz I, Jermendy G, Wilson PWF, Campaigne BN, Strojek K, Kerr L, etal. Effects of prandial versus fasting glycemia on cardiovascular outcomesin type 2 diabetes: The HEART2D trial. Diabetes Care. 2009;32(3):381-6.https://doi.org/10.2337/dc08-1671

  16. Secretaría de Gobernación. NOM Prevención, tratamiento y controlde la diabetes mellitus. México: Segob, 2010:1-40 [citado septiembre 2,2022]. Disponible en: https://www.cndh.org.mx/documento/nom-015-ssa2-2010-para-la-prevencion-tratamiento-y-control-de-la-diabetes-mellitus

  17. American Diabetes Association, Riddle M, ed. Standards of MedicalCare in diabetes — 2020; vol. 43. Arlington, USA: Diabetes.org, 2020:1-224. [citado septiembre 2, 2022]. Disponible en: https://www.sochob.cl/web1/wp-content/uploads/2019/12/Standards-of-MEdical-Care-in-Diabetes-2020.pdf

  18. De Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, MuntnerP, et al. Diabetes and hypertension: A position statement by the Americandiabetes association. Diabetes Care. 2017;40(9):1273-84. https://doi.org/10.2337/dci17-0026

  19. Secretaría de Salud CDMX. Principales servicios otorgados enunidades médicas Secretaría de Salud de la Ciudad de México 2010 -

  20. 2019. CDMX: Gobierno de la Ciudad de México, 2019 [citado octubre 7,2022]. Disponible en: http://www.data.salud.cdmx.gob.mx/portal/images/infosalud/archivos/servicios_otorgados/5.-%20Principales_servicios_otorgados_en_las_unidades_medicas_2010%20-%202019.pdf20. Secretaría de Salud CDMX. Segundo Informe de Gobierno. CDMX:Secretaría de Salud, 2020 [citado octubre 7, 2022]. Disponible en: https://www.salud.cdmx.gob.mx/conoce-mas/informacion-en-salud

  21. Basto-Abreu A, Barrientos-Gutiérrez T, Rojas-Martínez R, Rivera-DommarcoJ, Shamah-Levy T, Romero-Martínez M, et al. Prevalencia de diabetesy descontrol glucémico en México: resultados de la Ensanut 2016. SaludPublica Mex. 2020;62(1):50-9. https://doi.org/10.21149/10752

  22. Shi L. The impact of primary care: a focused review. Scientifica (Cairo).2012;2012:1-22. https://doi.org/10.6064/2012/432892

  23. Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J. Performance ofA1C for the classification and prediction of diabetes. Diabetes Care.2011;34(1):84 https://doi.org/10.2337/DC10-1235

  24. Aguilar-Salinas CA, Hernández-Jiménez S, Hernández-Ávila M,Hernández-Ávila JE. Acciones para enfrentar a la diabetes. Documento dePostura. México: Academia Nacional de Medicina de México, 2015:802. [citadooctubre 7, 2022]. Disponible en: http://anmm.org.mx/publicaciones/CAnivANM150/L15-Acciones-para-enfrentar-a-la-diabetes.pdf

  25. Wacher NH, Silva M, Valdez L, Cruz M, Gómez-Díaz RA. Causasde descontrol metabólico en atención primaria. Gac Med Mex.2016;152(1):350-6. [citado octubre 7, 2022]. Disponible en: https://www.anmm.org.mx/GMM/2016/n3/GMM_152_2016_3_350-356.pdf

  26. Mohseni M, Ahmadi S, Azami-Aghdash S, Mousavi-Isfahani H, MoosaviA, Fardid M, et al. Challenges of routine diabetes care during COVID-19era: A systematic search and narrative review. Prim Care Diabetes.2021;15(6):918-22 https://doi.org/10.1016/J.PCD.2021.07.017

  27. Nadal JF. Análisis Real World Data de algunas repercusiones de lapandemia de COVID-19 sobre el control metabólico de las personas conDM2. Diabetes Práctica. 2022;13:3743. https://doi.org/10.52102/diabet/pract/2022.1/art6

  28. Ammar A, Brach M, Trabelsi K, Chtourou H, Boukhris O, MasmoudiL, et al. Effects of COVID-19 home confinement on eating behaviourand physical activity: results of the ECLB-COVID19 International OnlineSurvey. Nutr. 2020;12:1583. https://doi.org/10.3390/NU12061583

  29. Ghosal S, Sinha B, Majumder M, Misra A. Estimation of effects of nationwidelockdown for containing coronavirus infection on worsening ofglycosylated haemoglobin and increase in diabetes-related complications:A simulation model using multivariate regression analysis. Diabetes MetabSyndr. 2020;14(1):319-23. https://doi.org/10.1016/j.dsx.2020.03.014

  30. Lear-Claveras A, González-álvarez B, Couso-Viana S, Clavería A, Oliván-Blázquez B. Analysis of clinical parameters, drug consumption and use ofhealth resources in a Southern European population with alcohol abusedisorder during COVID-19 pandemic. Int J Environ Res Public Health.2022;19(3). https://doi.org/10.3390/ijerph19031358

  31. Joensen LE, Madsen KP, Holm L, Nielsen KA, Rod MH, Petersen AA, etal. Diabetes and COVID-19: psychosocial consequences of the COVID-19pandemic in people with diabetes in Denmark—what characterizespeople with high levels of COVID-19-related worries? Diabet Med.2020;37(7):1146-54. https://doi.org/10.1111/DME.14319

  32. Potier L, Hansel B, Larger E, Gautier JF, Carreira D, Assemien R, et al.Stay-at-home orders during the COVID-19 pandemic, an opportunity toimprove glucose control through behavioral changes in type 1 diabetes.Diabetes Care. 2021;44(3):839-43. https://doi.org/10.2337/DC20-2019

  33. Formiga F, Franch-Nadal J, Rodriguez L, Ávila L, Fuster E. Inadequateglycaemic control and therapeutic management of adults over65 years old with type 2 diabetes mellitus in Spain. J Nutr Heal Aging.2017;21(10):1365-70. https://doi.org/10.1007/s12603-017-0869-4

  34. Hernández-Arroyo MJ, Díaz-Madero A, Enríquez-Gutiérrez E,Sánchez-Martín E, Hernández-Nieto C, Rodríguez-Benito M. Controlglucémico en pacientes diabéticos tipo 2 de edad avanzada. Intervenciónpara evitar riesgos. Med Fam Semer. 2020;46(7):457-63. https://doi.org/10.1016/j.semerg.2020.01.006




2020     |     www.medigraphic.com